000280058 001__ 280058
000280058 005__ 20250901102351.0
000280058 0247_ $$2doi$$a10.1016/j.tjpad.2025.100299
000280058 0247_ $$2ISSN$$a2274-5807
000280058 0247_ $$2ISSN$$a2426-0266
000280058 0247_ $$2altmetric$$aaltmetric:179728922
000280058 0247_ $$2pmid$$apmid:40683836
000280058 037__ $$aDZNE-2025-00895
000280058 041__ $$aEnglish
000280058 082__ $$a610
000280058 1001_ $$aMasebo, Lehané$$b0
000280058 245__ $$aCan non-pharmacological interventions change levels of neurofilament light in older adults at risk of dementia? A secondary analysis of the SCD-Well randomized clinical trial
000280058 260__ $$aCham$$bSpringer International Publishing$$c2025
000280058 3367_ $$2DRIVER$$aarticle
000280058 3367_ $$2DataCite$$aOutput Types/Journal article
000280058 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1756711808_32759
000280058 3367_ $$2BibTeX$$aARTICLE
000280058 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000280058 3367_ $$00$$2EndNote$$aJournal Article
000280058 520__ $$aOlder adults with subjective cognitive decline (SCD) and/or elevated neurofilament light (NfL), a neurodegeneration biomarker, are at increased risk of dementia. Non-pharmacological interventions offer a promising strategy for reducing dementia risk, yet none have utilized NfL as a marker of response in dementia prevention trials.To investigate the effects of two non-pharmacological interventions on NfL in older adults with SCD.SCD-Well was an 8-week observer-blinded, randomized, clinical trial with 6-month follow-up, and was a part of the Horizon 2020 European Union-funded 'Medit-Ageing' project. Data were analyzed from June 2022 to August 2024.Memory clinics at four sites in France, Germany, Spain, and UK.Participants were enrolled from March 2017 to January 2018 after fulfilling SCD research criteria and performing within the normal range on cognitive testing. Of the 147 participants enrolled, 140 were included in this secondary analysis (7 did not consent to venipuncture).Participants were randomly allocated to the Caring Mindfulness-Based Approach for Seniors (CMBAS) intervention or a structurally matched Health Self-Management Program (HSMP).Plasma NfL was measured at baseline (V1), post-intervention (V2), and 6-month follow-up (V3), using Single molecule array technology, and log-transformed for analyses.137 older adults with SCD provided NfL data (mean [SD] age: 72.7 [6.8] years; 62.0 % female; CMBAS, n = 70; HSMP, n = 67). NfL data were available at V1 (n = 136), V2 (n = 119) and V3 (n = 115). The visit-by-arm interaction was not statistically significant, and no significant changes in NfL were observed within the CMBAS or HSMP arms from V1 to V2. However, within the HSMP arm, NfL levels reduced from V1 to V3 (-0.10, 95 % confidence interval [-0.18 to -0.02]). Modified intention-to-treat analyses, which included 140 participants, supported these findings, and additionally recorded significant reductions in the HSMP arm from V1 to V2 (n = 140, -0.07 [-0.14 to -0.00]).In this study, NfL levels were reduced at 6-month follow-up after a health self-management program. Future interventions with longer duration, extended follow-up and clinical endpoints will help clarify whether NfL reductions are sustained over extended timeframes and translate to lower dementia incidence.ClinicalTrials.gov Identifier: (NCT03005652).
000280058 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000280058 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000280058 650_7 $$2Other$$aBehavior change
000280058 650_7 $$2Other$$aBlood
000280058 650_7 $$2Other$$aBlood-based biomarkers
000280058 650_7 $$2Other$$aFluid biomarkers
000280058 650_7 $$2Other$$aPsychological intervention
000280058 7001_ $$0P:(DE-HGF)0$$aWhitfield, Tim$$b1
000280058 7001_ $$aDemnitz-King, Harriet$$b2
000280058 7001_ $$aHeslegrave, Amanda$$b3
000280058 7001_ $$0P:(DE-HGF)0$$aPoisnel, Géraldine$$b4
000280058 7001_ $$0P:(DE-HGF)0$$aLutz, Antoine$$b5
000280058 7001_ $$0P:(DE-HGF)0$$aFrison, Eric$$b6
000280058 7001_ $$0P:(DE-2719)2814122$$aWirth, Miranka$$b7$$udzne
000280058 7001_ $$aHye, Abdul$$b8
000280058 7001_ $$0P:(DE-2719)2000032$$aJessen, Frank$$b9$$udzne
000280058 7001_ $$aAshton, Nicholas J.$$b10
000280058 7001_ $$aZetterberg, Henrik$$b11
000280058 7001_ $$0P:(DE-HGF)0$$aMarchant, Natalie L.$$b12
000280058 773__ $$0PERI:(DE-600)2782183-3$$a10.1016/j.tjpad.2025.100299$$gp. 100299 -$$n8$$p100299$$tThe journal of prevention of Alzheimer's disease$$v12$$x2274-5807$$y2025
000280058 8564_ $$uhttps://pub.dzne.de/record/280058/files/DZNE-2025-00895%20SUP.zip
000280058 8564_ $$uhttps://pub.dzne.de/record/280058/files/DZNE-2025-00895.pdf$$yOpenAccess
000280058 8564_ $$uhttps://pub.dzne.de/record/280058/files/DZNE-2025-00895.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000280058 909CO $$ooai:pub.dzne.de:280058$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000280058 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2814122$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000280058 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000032$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000280058 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000280058 9141_ $$y2025
000280058 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-05
000280058 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-05
000280058 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000280058 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJPAD-J PREV ALZHEIM : 2022$$d2024-12-05
000280058 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-05$$wger
000280058 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-05
000280058 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-05
000280058 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000280058 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJPAD-J PREV ALZHEIM : 2022$$d2024-12-05
000280058 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-05
000280058 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-05
000280058 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-05
000280058 920__ $$lyes
000280058 9201_ $$0I:(DE-2719)1710011$$kAG Wirth$$lBrain Resilience$$x0
000280058 9201_ $$0I:(DE-2719)1011102$$kAG Jessen$$lClinical Alzheimer’s Disease Research$$x1
000280058 980__ $$ajournal
000280058 980__ $$aVDB
000280058 980__ $$aUNRESTRICTED
000280058 980__ $$aI:(DE-2719)1710011
000280058 980__ $$aI:(DE-2719)1011102
000280058 9801_ $$aFullTexts